Schrödinger, Inc. has announced that its clinical stage MALT1 inhibitor, SGR-1505, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia who have failed at least two lines of therapy, including a Bruton's tyrosine kinase $(BTK.AU)$ inhibitor. This designation is intended to accelerate the development and review process for SGR-1505, highlighting its potential as a novel treatment option for this challenging condition. The Fast Track status provides Schrödinger with opportunities for more frequent interactions with the FDA and eligibility for expedited approval pathways. SGR-1505 is already being evaluated in a Phase 1 clinical study for relapsed/refractory B-cell malignancies, and initial results indicate a favorable safety profile and encouraging signs of efficacy.